Preclinical Antitumor Activity and Pharmacokinetics of Methyl-2-Benzimidazolecarbamate (FB642)
2002; Springer Science+Business Media; Volume: 20; Issue: 3 Linguagem: Inglês
10.1023/a
ISSN1573-0646
AutoresDesirée Hao, Jinee Rizzo, Stephanie Stringer, Rodney Moore, Jennifer Marty, Daniel L. Dexter, G. Mangold, James B. Camden, Daniel D. Von Hoff, Steven Weitman,
Tópico(s)PARP inhibition in cancer therapy
Referência(s)